Pay in 4 interest-free payments of $6.07 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Both treatment arms were receiving metformin alone (84%) or in combination with a DPP-4 inhibitor (16%) as background therapy
A medical assessment is the best way to determine whether peptide therapy is appropriate for you
Umpierrez GE, Cardona S, Chachkhiani D et al (2018) A randomized controlled study comparing a DPP4 inhibitor (linagliptin) and basal insulin (glargine) in patients with type 2 diabetes in long-term care and skilled nursing facilities: Linagliptin-LTC trial
Scientific Reports, 12, 512
US$ 27.88
US$ 21.82
US$ 23.48
US$ 25.62
US$ 22.92
US$ 25.64
